Dimopoulos Konstantinos, Pedersen Michael
Hæmatologisk Afdeling, Herlev Hospital, Herlev Ringvej 75, Herlev.
Ugeskr Laeger. 2012 Oct 1;174(40):2383-6.
Splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes is a low-grade malignant lymphoma, which primarily involves the spleen, the bone marrow and the blood. Even though the prognosis of the disease is good and there is a long overall survival, about two thirds of the patients will require treatment and in 10% of the patients the lymphoma will transform into a high-grade malignant lymphoma. The treatment of SMZL remains empirical, since there is lack of large, prospective studies. Without such studies, the best treatment modality cannot be established.
伴有或不伴有绒毛状淋巴细胞的脾边缘区淋巴瘤（SMZL）是一种低度恶性淋巴瘤，主要累及脾脏、骨髓和血液。尽管该疾病预后良好，总体生存期较长，但约三分之二的患者仍需要治疗，且10%的患者淋巴瘤会转化为高度恶性淋巴瘤。由于缺乏大型前瞻性研究，SMZL的治疗仍基于经验。没有此类研究，就无法确定最佳治疗方式。
